Action BDTX BLACK DIAMOND THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Black Diamond Therapeutics, Inc.

Actions

BDTX

US09203E1055

Temps réel estimé Cboe BZX
Autres places de cotation
 17:12:22 28/06/2024 		Varia. 5j. Varia. 1 janv.
4,785 USD +1,81% Graphique intraday de Black Diamond Therapeutics, Inc. -2,48% +67,97%
01/06 Black Diamond Therapeutics, Inc. présente des données cliniques prometteuses sur le Bdtx-1535 chez des patients atteints de glioblastome récurrent lors de la réunion annuelle de l'American Society of Clinical Oncology (Asco) en 2024 CI
16/05 BLACK DIAMOND THERAPEUTICS, INC. : Opinion positive de HC Wainwright ZM

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
AQ
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
GL
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
AQ
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GL
Black Diamond: Q1 Earnings Snapshot
AQ
Black Diamond Therapeutics : Reports First Quarter 2024 Financial Results and Provides Corporate Update - Form 8-K
PU
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
Black Diamond Therapeutics Announces Changes to Board of Directors
GL
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
GL
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
AQ
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
GL
Black Diamond: Q4 Earnings Snapshot
AQ
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
GL
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
AQ
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
GL
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
GL
Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
AQ
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
GL
Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action BDTX
  4. Actualités Black Diamond Therapeutics, Inc.
  5. Communiqués